Humana Rises as Medicare Advantage Sentiment Improves

Humana Inc. (HUM) is up 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be improving sentiment around Medicare Advantage economics rather than a single fresh company announcement. This could be because investors are still responding to a more favorable 2027 Medicare Advantage payment update from federal regulators, along with a recent analyst price-target increase tied to Medicaid data and steadier managed-care expectations.

Details:

Federal regulators finalized a 2027 Medicare Advantage payment increase that was better than many investors had feared, improving the earnings backdrop for insurers with large Medicare exposure.

Humana was one of the stronger beneficiaries when that payment update was released earlier this year, underscoring how sensitive the shares are to reimbursement changes.

A recent analyst note lifted Humana’s price target to $300 from $264 while keeping a neutral stance, citing Medicaid data as part of the framework for the revised view.

Humana’s first-quarter 2026 results also affirmed full-year adjusted guidance and projected Medicare Advantage membership growth of about 25% versus 2025, which supports the broader recovery case even if it was not a same-day catalyst.

Sources:

Humana, Centers for Medicare & Medicaid Services, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HUM Insider Trading Activity

$HUM insiders have traded $HUM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HUM stock by insiders over the last 6 months:

SANJAY K SHETTY (President, CenterWell) purchased 810 shares for an estimated $150,016

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HUM Hedge Fund Activity

We have seen 307 institutional investors add shares of $HUM stock to their portfolio, and 438 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 3,831,860 shares (-65.9%) from their portfolio in Q1 2026, for an estimated $664,406,205
BANK OF NEW YORK MELLON CORP removed 1,479,679 shares (-70.6%) from their portfolio in Q1 2026, for an estimated $256,561,541
SESSA CAPITAL IM, L.P. added 1,408,833 shares (+60.8%) to their portfolio in Q1 2026, for an estimated $244,277,553
PZENA INVESTMENT MANAGEMENT LLC added 1,398,774 shares (+34.3%) to their portfolio in Q1 2026, for an estimated $242,533,423
CAPITAL RESEARCH GLOBAL INVESTORS added 1,099,839 shares (+inf%) to their portfolio in Q1 2026, for an estimated $190,701,084
FRANKLIN RESOURCES INC removed 981,758 shares (-78.2%) from their portfolio in Q1 2026, for an estimated $170,227,019
GOLDMAN SACHS GROUP INC added 926,632 shares (+94.6%) to their portfolio in Q1 2026, for an estimated $160,668,722

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HUM Congressional Stock Trading

Members of Congress have traded $HUM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $HUM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$HUM Analyst Ratings

Wall Street analysts have issued reports on $HUM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $HUM, check out Quiver Quantitative's $HUM forecast page.

$HUM Price Targets

Multiple analysts have issued price targets for $HUM recently. We have seen 17 analysts offer price targets for $HUM in the last 6 months, with a median target of $316.0.

Here are some recent targets:

Ben Hendrix from RBC Capital set a target price of $415.0 on 07/09/2026
Sarah James from Cantor Fitzgerald set a target price of $300.0 on 07/07/2026
Kevin Fischbeck from B of A Securities set a target price of $380.0 on 06/24/2026
Elizabeth Suzuki from Evercore ISI Group set a target price of $370.0 on 06/11/2026
Lisa Gill from JP Morgan set a target price of $316.0 on 06/08/2026
Ann Hynes from Mizuho set a target price of $390.0 on 06/08/2026
Erin Wright from Morgan Stanley set a target price of $249.0 on 06/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.